Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Catalyst Pharm Inc (CPRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Biotech's Flying Under The Radar

Biotech investors spend a ton of time considering what the cure for cancer could be or the next invention that could eliminate a rare disease. It's difficult to keep track of the advancements and developments...

ESPR : 57.68 (-0.14%)
AEZS : 2.19 (-1.35%)
PPCB : 0.1300 (-17.46%)
GERN : 2.00 (+1.52%)
CPRX : 4.11 (+0.24%)
Analysis: Positioning to Benefit within Office Depot, ImmunoGen, Cedar Realty Trust, Carbo Ceramics, Consolidated Communications, and Catalyst Pharmaceuticals -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Office Depot, Inc. (NASDAQ:ODP),...

CDR : 6.07 (+0.33%)
CRR : 9.72 (-0.10%)
IMGN : 6.39 (-4.63%)
ODP : 3.44 (+2.38%)
CNSL : 12.58 (-1.33%)
CPRX : 4.11 (+0.24%)
Biotech Stock Roundup: Regeneron Down on Eylea Data, Biogen-Alkermes in MS Deal

While there were not too many updates this week, companies like Regeneron (REGN) and Biogen were in the news related to their pipeline.

CTMX : 21.83 (+0.78%)
REGN : 385.45 (+0.61%)
CPRX : 4.11 (+0.24%)
ALKS : 52.24 (+1.32%)
AMGN : 176.93 (+1.15%)
BIIB : 329.31 (+1.78%)
Catalyst Pharmaceuticals, Inc. Prices Previously Announced Public Offering of Common Stock

CORAL GABLES, FL--(Marketwired - Nov 28, 2017) - Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) today announced the pricing of its previously announced underwritten public offering. The Company announced...

CPRX : 4.11 (+0.24%)
Catalyst (CPRX) Reports Positive Phase III Data on Firdapse

Catalyst (CPRX) reported encouraging top-line results from a phase III study for its pipeline candidate, Firdapse, for the treatment of Lambert-Eaton myasthenic syndrome.

LGND : 134.24 (-1.32%)
SCMP : 17.00 (+1.49%)
BMRN : 90.82 (+2.59%)
CPRX : 4.11 (+0.24%)
Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

Catalyst Pharmaceuticals, Inc. (NasdaqCM:CPRX) announced today that it has commenced an underwritten public offering of 11 million shares of its common stock. Catalyst also intends to grant the underwriters...

CPRX : 4.11 (+0.24%)
Catalyst Pharmaceuticals Announces Positive Top-Line Results from Second Phase 3 Clinical Trial of Firdapse(R) in Patients with Lambert-Eaton Myasthenic Syndrome

-- Treatment with Firdapse Achieved Statistical Significance for Co-Primary Endpoints and Secondary Endpoint --

CPRX : 4.11 (+0.24%)
Catalyst Initiates Phase II Study for Pipeline Drug Firdapse

Catalyst (CPRX) announces the initiation of phase II study to evaluate safety, tolerability and efficacy of its lead pipeline candidate, Firdapse.

LGND : 134.24 (-1.32%)
SCMP : 17.00 (+1.49%)
BMRN : 90.82 (+2.59%)
CPRX : 4.11 (+0.24%)
Catalyst Pharmaceuticals Announces Phase 2 Study of Firdapse(R) in Ambulatory Patients with Spinal Muscular Atrophy (SMA)

Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological...

CPRX : 4.11 (+0.24%)
Generic Drugs Stock Performance Review -- Catalyst Pharma, Flexion Therapeutics, Supernus Pharma and Allergan

If you want a Stock Review on CPRX, FLXN, SUPN, or AGN then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. DailyStockTracker.com shifts focus on Catalyst...

SUPN : 39.45 (+2.20%)
AGN : 171.64 (+0.41%)
CPRX : 4.11 (+0.24%)
FLXN : 24.85 (+1.64%)
Catalyst (CPRX) Posts Narrower-Than-Expected Loss in Q3

Catalyst Pharma (CPRX) remains focused on the development of its pipeline candidate firdapse in the third quarter of 2017.

LGND : 134.24 (-1.32%)
EXEL : 26.37 (+1.62%)
ADAP : 7.32 (-0.67%)
CPRX : 4.11 (+0.24%)
Catalyst Pharmaceuticals Announces Third Quarter 2017 Financial Results and Provides Corporate Update

Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular...

CPRX : 4.11 (+0.24%)
What's in Store for Catalyst (CPRX) This Earnings Season?

Catalyst (CPRX) focus will be on pipeline and regulatory updates at the third-quarter earnings call.

AGEN : 3.54 (+0.57%)
AMED : 55.41 (+1.89%)
ALNY : 124.76 (+0.89%)
CPRX : 4.11 (+0.24%)
Catalyst Pharmaceuticals to Hold Third Quarter Financial Results Conference Call and Webcast on Thursday, November 9th, 2017

Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological...

CPRX : 4.11 (+0.24%)
Catalyst Pharmaceuticals Completes Enrollment in Second Phase 3 Trial of Firdapse(R) in Patients with Lambert-Eaton Myasthenic Syndrome

-- Top-Line Results Expected in Early December --

CPRX : 4.11 (+0.24%)
Catalyst Pharmaceuticals to Present at 16th Annual BIO Investor Forum

Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating neuromuscular and neurological...

CPRX : 4.11 (+0.24%)
Generic Drugs Stock Performance Review -- Catalyst Pharma, Flexion Therapeutics, Supernus Pharma, and Allergan

If you want a Stock Review on CPRX, FLXN, SUPN, or AGN then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. DailyStockTracker.com revisits the Generic Drugs...

SUPN : 39.45 (+2.20%)
AGN : 171.64 (+0.41%)
CPRX : 4.11 (+0.24%)
FLXN : 24.85 (+1.64%)
Catalyst (CPRX) Focused on Two Lead Pipeline Candidates

: Catalyst (CPRX) remains focused on development of its two lead pipeline candidates, Firdapse and CPP-115.

JNJ : 141.94 (+0.20%)
NVS : 84.64 (+0.20%)
CPRX : 4.11 (+0.24%)
PFE : 37.17 (+1.95%)
Technical Snapshots for These Generic Drugs Stocks -- Catalyst Pharma, Flexion Therapeutics, Supernus Pharma, and Lannett

If you want a Stock Review on CPRX, FLXN, SUPN, or LCI then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. Today, DailyStockTracker.com shifts focus on...

LCI : 27.65 (-1.60%)
SUPN : 39.45 (+2.20%)
CPRX : 4.11 (+0.24%)
FLXN : 24.85 (+1.64%)
Catalyst Pharmaceuticals Provides Update on the Status of its Firdapse Development Activities

-- FDA grants Special Protocol Assessment agreement for Phase 3 MuSK-MG trial --

CPRX : 4.11 (+0.24%)

Van Meerten Stock Picks

5 Great Mid Caps
  Today you will find that I have varied a little bit from my usual search criteria.
KBH +0.07 , IPGP +4.38 , FSLR +1.43 , NVR -3.24 , TTWO +2.88
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

Barchart Morning Call

OVERNIGHT MARKETS AND NEWS Mar E-mini S&Ps ( ESH18 +0.22%) this morning are up +0.16% and European stocks are down -0.34% at a 1-week low. Investors continue to pour money into U.S. equity funds at the expense of European stock funds.... Read More

Chart of the Day

Chart of the Day

Maximus (MMS) is the Barchart CHartr of the Day.  The governmental consulting firm has a Trend Spotter buy signal, a Weighted Alpha of 32.85+ and gained 31.28% in the last year.
Read More

Brugler Ag Report

Today's Commentary

Corn futures are continuing their tight trading range on Friday, with most contracts down 1 to 1 1/4 cents. A private export sale of 134,503 MT of corn was sold to Costa Rica as announced by the USDA through their daily export reporting system. Total...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.